The A to I editing landscape in melanoma and its relation to clinical outcome

RNA editing refers to not transient RNA modifications that occurs after transcription and prior to translation by the ribosomes. RNA editing is more widespread in cancer cells than in non-transformed cells and is associated with tumorigenesis of various cancer tissues, however, RNA editing can also generate neo-antigens that expose tumour cells to host immunosurveillance. Global RNA editing in melanoma and its relevance to clinical outcome currently remains poorly characterized. The present study compared RNA editing as well as gene expression in tumour cell lines from melanoma patients of short or long metastasis-free survival, patients relapsing or not after immuno- and targeted therapy and patients harbouring BRAF or NRAS mutations. Overall design: Single-end RNAseq of 72 melanoma cell cultures